

SHAN Beteiligungsgesellschaft m.b.H.

Claims:

1. A hybrid polypeptide comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein.
2. A hybrid polypeptide according to claim 1 wherein the hybrid polypeptide comprises at least one complete allergenic protein.
3. A hybrid polypeptide according to claim 2 wherein the hybrid polypeptide comprises at least two complete allergenic proteins.
4. A hybrid polypeptide according to claim 1 wherein the hybrid polypeptide comprises at least one fragment of an allergenic protein which fragment has a substantially reduced allergenic activity compared with the allergenic protein from which it is derived.
5. A hybrid polypeptide according to claim 4 wherein the hybrid polypeptide comprises fragments of at least two different allergenic proteins all of which fragments have a substantially reduced allergenic activity compared with the respective allergenic proteins from which they are derived.
6. A hybrid polypeptide according to any of claims 1-5 characterized in that it comprises at least three different allergenic proteins or fragments thereof.
7. A polynucleotide encoding a polypeptide according to any of claims 1-6.
8. The use of a polynucleotide according to claim 7 for the preparation of a DNA vaccine.
9. A cell transfected or transformed with a polynucleotide comprising a polynucleotide according to claim 7.

10. A pharmaceutical composition containing a polypeptide according to any of claims 1-6, a polynucleotide according to claim 7 or a cell according to claim 9.

11. A pharmaceutical composition according to claim 10 which is a vaccine composition.

12. A pharmaceutical composition according to claim 10 or 11 further containing an adjuvant.

13. A method for the preparation of a hybrid polypeptide according to any of claims 1-6 comprising the following steps:

- a) providing a polynucleotide encoding the hybrid polypeptide;
- b) introducing said polynucleotide into a host cell; and
- c) culturing the host cell obtained in step b) under conditions such that the hybrid polypeptide is expressed; and
- d) recovering the expression product from the cell.

14. A method according to claim 13 wherein the polynucleotide encoding the hybrid polypeptide is prepared using PCR technology.

15. A method for the preparation of a hybrid polypeptide according to any of claims 1-6 characterized in that the polypeptide is prepared by chemical synthesis.

16. The use of a hybrid polypeptide according to any of claims 1-6, or of a polynucleotide according to claim 7, or of a cell according to claim 9 for the preparation of a medicament for the treatment of an allergic disorder.

17. The use of a hybrid polypeptide according to any of claims 1-6, or of a polynucleotide according to claim 7 or of a cell according to claim 9 for the preparation of a medicament for prophylactic vaccination or tolerance induction.

18. The use of a hybrid polypeptide according to any of claims 1-6 for the detection of antibodies against an allergenic protein in a sample.

19. The use according to claim 18 wherein the detection is performed by in vitro antibody tests, tests using cells and in vivo tests.

19. The use according to claim 18 wherein the detection is performed by in vitro antibody tests, tests using cells and in vivo tests.